 This is a Phase 2, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the dosing interval, efficacy and safety of SST-0225 5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period for the treatment of pain associated with DOMS. 